1. Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes
- Author
-
Hideki Kamiya, Takahiro Tosaki, Miho Moribe, Megumi Shiroma, Jiro Nakamura, Kaori Tsubonaka, Yuki Nakaya, Hitomi Asai, Tatsuhito Himeno, Tomoyo Nishida, Kaori Toyota, Yoshiro Kato, and Masaki Kondo
- Subjects
Male ,Blood Pressure ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Kidney Function Tests ,Gastroenterology ,chemistry.chemical_compound ,0302 clinical medicine ,Glucosides ,Medicine ,Sorbitol ,Dapagliflozin ,Aged, 80 and over ,SGLT2 inhibitor ,General Medicine ,Middle Aged ,Body Composition ,Original Article ,Female ,Glomerular Filtration Rate ,Adult ,medicine.medical_specialty ,oral hypoglycemic agent ,visceral fat ,Renal function ,030209 endocrinology & metabolism ,Thiophenes ,Intra-Abdominal Fat ,03 medical and health sciences ,Internal medicine ,Internal Medicine ,Humans ,Hypoglycemic Agents ,Benzhydryl Compounds ,Canagliflozin ,Sodium-Glucose Transporter 2 Inhibitors ,Aged ,Glycated Hemoglobin ,Creatinine ,business.industry ,renal function ,Body Weight ,Type 2 Diabetes Mellitus ,medicine.disease ,Ipragliflozin ,Endocrinology ,chemistry ,Diabetes Mellitus, Type 2 ,glycemic control ,Glycated hemoglobin ,business ,Tofogliflozin - Abstract
Objective and Methods An SGLT2 inhibitor (ipragliflozin, dapagliflozin, luseogliflozin, tofogliflozin, or canagliflozin) was administered to 132 outpatients with type 2 diabetes mellitus with or without other antidiabetic drugs for 6 months to evaluate its efficacy, the incidence of adverse events, and its influence on the renal function. Results The patient's mean glycated hemoglobin level significantly improved from 7.52±1.16% to 6.95±0.98% (p
- Published
- 2017